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Australia
objectives: The aim was to determine the cost-effectiveness of colonic stent inser-
tion for the management of malignant bowel obstructions. Colonic stents are a 
minimally invasive alternative to open surgery for patients medically unfit for single 
stage surgery. MethoDs: Two economic models were developed. The first compared 
patients who received palliative or definitive stents and were not medically fit for 
re-anastomosis. The second compared patients who received stents as a bridge-to-
surgery and were medically fit for a second stage of two-stage surgery, this included 
colostomy or Hartmann’s procedure. ResultsFor patients requiring palliation, the 
cost of colonic stent insertion was estimated to be $17,809 compared to $20,516 for 
palliative colostomy (a saving of $2,707). The benefits associated with both proce-
dures were 0.099 QALYs and 0.089 QALYs gained, respectively, an incremental benefit 
of 0.01 QALYs per patient. For patients requiring a bridge-to-surgery, the cost of 
colonic stent insertion was estimated to be $29,729, compared to $30,169 for patients 
that received multi-stage surgery (either a colostomy or a Hartmann’s procedure). 
This represented a cost savings of $440. The estimated average patient would gain 
0.510 QALYs compared to 0.458 QALYs in the multi-stage surgery group. This yields 
an incremental benefit of 0.052 QALYs per patient. The main drivers of both models 
were the technical and clinical success of the stent insertion, and length of hospital 
stay following the procedures. The probability of a resection with primary anas-
tomosis after insertion of a stent and the cost of stenting were also drivers in the 
bridge-to-surgery model. conclusions: In terms of cost-effectiveness, colonic 
stent insertion for malignant bowel obstruction in patients requiring palliation or 
a bridge-to-surgery dominated the current alternative surgical procedures.
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objectives: The aim of this study is to develop and validate a decision-analytic 
model describing the current course of disease, including treatment, in metastatic 
colorectal cancer. This baseline model will serve as the comparator in analyses of the 
(cost-) effectiveness of new treatment strategies. MethoDs: An individual-based 
micro-simulation model was constructed based on the disease states a patient 
may experience after a diagnosis of metastatic colorectal cancer. The states include 
first-line second-line and third-line treatment, as well as states of progression of 
disease after first-, second- or third-line, finally a death state is included. Time spent 
in each disease state was predicted using log-logistic, log-normal or weibull survival 
models, each dependent on a number of patient characteristics. All survival models 
and patient characteristics were based on patient-level data, provided by the CAIRO 
trial (NCT00312000). Two oncologists evaluated the model for face validity, the model 
was further validated by comparing various model outcomes with the original data, 
the national cancer registry and a population based study. results: There were no 
significant differences in patient and treatment characteristics, nor intermediate 
and overall survival estimates between the simulated and original patient-level 
data. External validation with national cancer registry data showed few differences 
in survival with the simulated data. Additionally the simulated survival did not 
significantly differ from the survival as recorded in a pilot oxaliplatin study of 119 
patients who were observed in the same timeframe as the RCT. conclusions: The 
micro-simulation decision model described in this article underwent an internal 
and external validation and can be used to evaluate new possibilities for research 
and treatment in metastatic colorectal cancer.
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objectives: The evaluation of the economic consequences of 21-gene RT-PCR assay 
OncotypeDX introduction to the reimbursement scheme of National Organization 
for Health Provision-EOPYY. MethoDs: A decision tree was developed concerning 
two treatment scenarios for the year 2013: a) chemotherapy admission according the 
common treatment practice without the application of the test vs b) chemotherapy 
admission depending on the results of the test. The sub-group of breast cancer 
patients appropriate for applying the test was determined according international 
guidelines and included early stage breast cancer women with hormone receptor 
positive and lumph node negative age ≤ 65 years. Cancer incidence was derived from 
ELSTAT and OECD base, while some assumptions were made concerning the age 
structure and disease stage of the population. The percentages of women assessed 
as high risk (score> 31) for recurrence were obtained from EOPYY data for 2013. The 
estimated cost for OncotypeDX test was set according the EOPYY reimbursement 
price (€ 2,848 for 2013). Cost of chemotherapy and other cost items (eg laboratory 
sectable osteosarcoma using national guideline recommendations. MethoDs: 
An economic disease model was developed based on recommendations from the 
2013 NCCN Clinical Practice Guidelines in Oncology for bone cancer. The model 
quantified resource use for diagnosis, 12 months of treatment, and 12 months 
of surveillance of a metastatic unresectable osteosarcoma patient. Costs in 2014 
dollar value were derived from publically available sources for reimbursement of 
CPT codes, HCPCS codes, and generic WAC prices for medications. Chemotherapy 
dosing was based on NCCN recommended treatment regimens. results: The 
diagnostic cost was estimated to be $1,706 per patient. Treatment costs, consist-
ing of stereotactic radiosurgery and chemotherapy with drug monitoring, varied 
widely across the four NCCN recommended regimens due to differences in the 
price of pharmacotherapy. The chemotherapy regimens were estimated to be the 
major cost components associated with this disease. Doxorubicin, cisplatin, and 
high-dose methotrexate cost $103,051 per patient; doxorubicin and cisplatin cost 
$17,549 per patient; doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide 
cost $38,404 per patient; and cisplatin, ifosfamide, and epirubicin cost $38,936 per 
patient. Additionally, stereotactic radiosurgery was estimated at $2,755 per patient, 
and the cost of drug monitoring during the one year of chemotherapy averaged to 
$5,899 per patient. Additionally, one year of disease surveillance cost $4,264 per 
patient. conclusions: A guideline-based disease model can assist health plans 
to better understand and anticipate the expected diagnosis, treatment, and sur-
veillance resources and costs for unresectable metastatic osteosarcoma patients.
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objectives: The objective of this cost study was to measure the resource utilisa-
tion and the direct costs associated with health care management of metastatic 
malignant melanoma (mMM) in Slovakia and provide a basis for cost-effectiveness 
evaluations. MethoDs: The cross-sectional survey was performed and included 3 
oncologists experienced in mMM management. The survey was performed to obtain 
the information on the management of patients with mMM and to estimate the 
direct costs of the disease. The studied population were 3 cohorts of mMM patients 
which are usually identified as the health states in the cost-effectiveness models: 
“Before progression“, “Disease progression“ and “Terminal care“. Costs of drugs 
were assesed separately from health states and rated particularly according to BRAF 
positivity. The cost data were assessed for the year 2013. All types of health care used 
in mMM management were evaluated (outpatient and inpatient visits, diagnostics, 
prescription drugs and medical examinations). Costs of adverse events (AEs) were 
set for one single event. results: The most frequent treatment regimens used in 
the first treatment line of BRAF mutant and BRAF negative patients were identical 
- dacarbazin (94.9% of treated patients), fotemustin (4.5%) and ipilimumab (0.6%). 
Monthly costs of mMM management in addition to the active treatment in the 
state “Before progression“ count for 6.64% (€ 188.51/patient), during the “Disease 
progression“ it was 45.56% (€ 1 294.31/patient) and during the “Terminal state of 
patient“ 47.80% (€ 1 358.02/patient). Adverse event (AE) costs were evaluated for 
grade 3 and 4. The most costly AEs were neutropenia (€ 1 014.66), fever (€ 364.87) and 
rash (€ 230.35). conclusions: In the management of mMM (excluding the active 
drug cost), the most expensive are the costs of hospitalization and symptomatic 
treatment. The most costly period is the “Terminal state“.
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objectives: The EHR4CR 4-year research partnership between the European Union 
and the European Federation of Pharmaceutical Industries and Associations (EFPIA) 
has developed a platform for the trustworthy reuse of hospital electronic health 
records’ data for clinical research. A cost-benefit assessment (CBA) was conducted 
from the pharmaceutical industry perspective to assess the value of the first two 
EHR4CR clinical research scenarios (S): Protocol feasibility assessment (S1), and 
Patient identification and recruitment (S2), either used individually or sequentially 
within a clinical trial workflow, versus current practices. MethoDs: The EFPIA 
partners have conducted a resource utilization assessment to calculate the actual 
person-time and cost of performing S1 and S2 for one oncology clinical study (Phase 
II or Phase III) as reference case. Assuming that an estimated 50% reduction in actual 
person-time and cost under EHR4CR conditions would directly translate in acceler-
ated time to market (TTM), potential benefits to global pharmaceutical industry were 
derived using global market values (2012) of oncology products1. Absolute cost-ben-
efit analyses were conducted using Monte-Carlo simulations. results: Compared 
to current practices, individual EHR4CR scenarios S1 and S2 have yielded efficiency 
gains of 134 days and 37 days respectively, and of 171 days when used sequentially. 
Should these efficiency gains from study design optimisation translate in faster 
TTM, corresponding estimated benefits for the global pharmaceutical oncology 
franchise could reach 160,45, and 205 Million € , respectively. conclusions: This 
CBA is the first to assess the value of EHR4CR scenarios for oncology clinical trials. 
The results confirm that the EHR4CR platform could generate substantial added 
value for pharmaceutical industry should its efficiency gains translate in faster 
TTM. Further benefits are expected from the EHR4CR platform in other therapeutic 
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score. results: Mean DMC per QoL was lowest in Pr, and highest in Hem cancers 
(ranged 60.1-195.1 TL/global QoL score) (Pr< Gy< CR≈Gas≈Br≈Lng≈H&N< Hem). QoL 
was lowest in Gy and highest in CR (ranged 53,1-65,2) (Gy< Lng< Pr< Br≈Hem≈H&NC). 
Total DMC ranged from 3124-13557 TL (Pr≈GY< Br< Gas≈CR< Lng≈H&N< Hem). 
Depending on the type of the cancer the association between DMC and QoL could 
be in different directions (the correlation between DMC and role functioning was 
positive in Gas, while it was negative in H&N cancer). conclusions: For a fixed 
period of time the total DMC associated with the management of different types of 
cancers vary substantially. As expected the total cost does not however purchase 
equal amount of QoL for each type of cancer. For those cancers with higher DMC 
per QoL, we should consider implementing wider psychosocial support measures. 
Depending on the type of cancer DMC may reflect disease progression leading to 
decreased QoL, or it may reflect presence of an effective and aggressive manage-
ment leading to increased QoL.
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Cost-EffECtivENEss ModEl of PErtuzuMaB iN CoMBiNatioN with 
trastuzuMaB aNd doCEtaxEl CoMParEd with trastuzuMaB iN 
CoMBiNatioN with doCEtaxEl for thE 1st liNE trEatMENt of hEr2+ 
MEtastatiC BrEast CaNCEr iN ColoMBia
Saenz Ariza S.A.
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objectives: To evaluate the cost effectiveness of Pertuzumab plus Trastuzumab 
and docetaxel (PTD) vs. Trastuzumab and docetaxel (TD) for the first-line treat-
ment in patients with HER2+ metastatic breast cancer in Colombia. MethoDs: For 
the evaluation of the cost-effectiveness a health economic area under the curve 
model was developed. The model considers three health states: progression-free 
survival, disease progression and death. The proportion of patients in each health 
state were derived using patient level data from the CLEOPATRA trial like efficacy 
and safety results, with the exception where overall survival (OS) utilized data from 
longer term clinical registries. The primary model outcome is the ICER cost per QALY 
gained in the first-line PTD vs. TD. The following main model input data assump-
tions were applied for the base case analysis: Time horizon: 15 years; model cycle 
length: weekly; 3) reference prices for drugs in Colombia, except for Pertuzumab 
which was supplied by the manufacturer; 4) treatment duration: actual treatment 
duration from the CLEOPATRA study extrapolated using an exponential function; 
and 5) discount rates: annual rate of 3.0% for both, future costs and health ben-
efits. results: The outcomes over a time horizon show an increase in mean OS 
time for patients assigned to the PTD group as compared to those in the TD of 0.72 
years. Mean QALYs are also higher in the PTD group than in the TD group 0.58 QALYs. 
The addition of Pertuzumab leads to higher total average treatment costs of $143.529 
dollars per patient compared to the TD group. These findings result in an ICER of 
$200.509 per life year gained and of $249.582 per QALY gained. conclusions: 
When compared to commonly accepted cost-effectiveness thresholds, these results 
exceed commonly applied willingness-to-pay thresholds, but Pertuzumab becomes 
a therapeutic alternative that offers a better health outcome.
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objectives: To assess the cost-effectiveness of ipilimumab compared to dac-
arbazine as first-line treatment in patients with advanced metastatic mela-
noma. MethoDs: A three-state Markov (progression-free, progression and death) 
with three-week cycles model using the Spanish Healthcare System perspective was 
developed over a lifetime horizon. The clinical profile of ipilimumab (3 mg/kg) was 
obtained from a pooled dataset of chemotherapy naive patients from four phase 
II and phase III studies, and from the CA184-024 trial for dacarbazine. Parametric 
extrapolation methods were used to project survival over lifetime. Costs included 
were: drug acquisition (ex-factory price -7,5% mandatory rebate) and administra-
tion, medical/terminal care, and adverse events management. Unit costs were 
derived from Spanish health care cost databases (Euros, 2013). For drugs with a 
double-pricing system (like ipilimumab), costs were based upon the official noti-
fied prices in Spain. Costs and benefits were discounted at 3%. Utility values were 
taken from the CA184-024 trial. Univariate and probabilistic sensitivity analyses 
(PSA) were performed. results: The life years (LYs) and quality-adjusted life years 
(QALYs) gained with ipilimumab as first-line treatment over dacarbazine were 2.01 
and 1.68, respectively. The incremental cost of using ipilimumab versus dacarbazine 
was 69,598 € . The incremental cost-effectiveness ratio (ICER) and the incremental 
cost-utility ratio (ICUR) were 34,566€ /LY gained and 41,459€ /QALY, respectively. PSA 
showed that ipilimumab is up to 100% and 90% likely to be cost-effective at the 
threshold established by the NICE for oncology drugs that meet ‘End-of-Life’ crite-
ria (50,000-62,000€ ) for ICER and ICUR, respectively. Additionally, at the threshold 
acceptable in Spain (30,000-45,000€ ) the likelihood of ipilimumab being cost-effec-
tive is up to 94% and 66% for ICER and ICUR, respectively. conclusions: Results 
suggest that ipilimumab is a cost-effective alternative for previously untreated 
patients with advanced metastatic melanomain Spain.
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objectives: MR colonography may have potential as a colorectal cancer (CRC) 
screening tool since it has comparable test characteristics as colonoscopy but 
is less invasive. Furthermore, innovators in the field of MR technology are striv-
tests) were based on official reimbursed prices. results: Out of 4,934 newly diag-
nosed breast cancer women, 27.5% (1,357) were appropriate for the test application. 
Only 35% of the women undertaken the oncotype test (N= 1,357) were found as high 
risk for recurrence (N= 475). The average total cost of chemotherapy treatment was 
estimated to € 8,271 from which more than 80% refer to pharmaceuticals. The total 
treatment cost for women who didn’t undertake the test reached to € 10.9 mil., 
while the relevant cost for women who undertook the test was estimated to € 8 mil.  
conclusions: The introduction of Oncotype DX® to the Greek health care system 
had as a result annual cost savings of almost € 3 million and avoidance of unneces-
sary chemotherapy treatment (and associated complications) to more than 880 
women.
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objectives: The degree of benefit from colonoscopy in the prevention of colorectal 
cancer (CRC) is highly dependent on the quality of bowel cleansing. In a rand-
omized study of patients undergoing screening colonoscopy in Germany (MODEC), 
2L polyethylene glycol with electrolytes + ascorbate components (PEG+ASC) resulted 
in numerically higher overall polyp/adenoma detection rates (PDR/ADR) and sig-
nificantly higher right-sided PDR/ADR than sodium picosulfate/magnesium citrate 
(NaPic/MgCit), together with better bowel cleansing. The objective of the model 
was to examine the socioeconomic impact of bowel cleansing quality on the effec-
tiveness of CRC screening in the eligible German population. MethoDs: A cost-
consequence model was constructed to compare the total cost of colonoscopy and 
treatment of subsequent CRC over a 10-year period in a cohort of 10,000 patients 
aged ≥ 55 years receiving 2L PEG+ASC or NaPic/MgCit prior to colonoscopy. The 
rates of successful bowel cleansing, completed colonoscopies, and PDR/ADR were 
obtained from the MODEC study. Published rates of surveillance colonoscopy, associ-
ated costs and health care resource utilization in Germany were used, with costs 
inflated to 2013 prices. results: The model predicts that the use of 2L PEG+ASC 
versus NaPic/MgCit increases the average per patient cost associated with colonos-
copy by € 67. However, better bowel cleansing and numerically higher overall PDR/
ADR achieved using 2L PEG+ASC rather than NaPic/MgCit avoids progression to CRC 
in 166 patients, due to early detection, equating to an average per patient saving in 
CRC treatment costs of € 488. The model shows that the use of 2L PEG+ASC versus 
NaPic/MgCit at screening/surveillance colonoscopy leads to an average overall cost 
saving of € 420 per patient over 10 years. conclusions: Modeling of long-term 
outcomes shows that using an effective bowel cleansing preparation in CRC screen-
ing may reduce the number of patients developing CRC, and may lead to reduced 
CRC treatment costs.
PCN98
a Cost-CoNsEquENCE aNalysis of huMaN PaPilloMavirus vaCCiNatioN 
iN roMaNia
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objectives: The objective of the study was to estimate the potential cost and epi-
demiological impact of a Human Papillomavirus (HPV) mass vaccination in Romania 
for the two available vaccines in the Romania: AS04 adjuvanted HPV16/18 vac-
cine (AS04V) and the HPV6/11/16/18 vaccine (QV). MethoDs: We applied, to the 
Romanian settings, a population steady state model previously published with a 
one year time horizon estimating the effect (cases and costs) of a vaccination pro-
gramme. The number of cases and costs (in RON – Romanian National Currency) 
were collected from the hospitalization Diagnosis Related Group database for the 
year 2012. cervical cancer (CC) and genital warts (GW) were considered. Vaccine 
effectiveness was approximated by weighting vaccine-type and non-vaccine-type 
efficacy with HPV distribution reported for GW (literature) and CC (HPV Centre) for 
each vaccine. One way sensitivity analysis was conducted on key input param-
eters. results: HPV vaccination would save17,706,490 RON with AS04V and 
16,432,592 RON with QV. An additional 820 CC-related hospitalisations amounting 
to a cost difference of 1,273,898 RON was estimated in favour of the AS04V. A total 
of 205 cases of GW prevented and 153,395 RON associated costs were estimated in 
favour of the QV. The total cost difference amounted to 1,120,503 RON. Robustness of 
the results was confirmed by sensitivity analyses”. conclusions: Implementing 
the AS04V would result in > 1 million RON saved versus the QV mainly due to a dif-
ference of extra 820 CC cases prevented that completely offsets the benefit associ-
ated with the prevention of GW. The observed difference is mainly due to higher 
protection associated with non-vaccine types for AS04V.
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objectives: The new cancer treatment modalities are improving survival rates 
today and one of the main outcomes is the improved health related quality of 
life (QoL). Prolonged survival also increases the financial burden of cancer care on 
health care systems. In this study we aimed to analyze the associations between 
QoL and direct health care costs in different types of cancers. MethoDs: We evalu-
ated QoL (EORTC QLQ-C30) and direct medical costs (DMC) in 350 patients with lung 
(Lng), breast (Br), hematological (Hem), head and neck (H&N), colorectal (CR), gastric 
(Gas), gynecological (Gy), and prostate (Pr) cancers. The DMC data of each patient in 
the following 3-month period after QoL assessment was obtained from the hospi-
tal finance department database. DMC per QoL point was calculated by DMC/QoL 
